Pharmacophore discovery using the Inductive Logic Programming system PROGOL

被引:80
作者
Finn, P
Muggleton, S
Page, D [1 ]
Srinivasan, A
机构
[1] Univ Louisville, Dept Engn Math & Comp Sci, Speed Sci Sch, Louisville, KY 40292 USA
[2] Pfizer Ltd, Cent Res, Computat Chem, Ramsgate Rd, Sandwich CT13 9NJ, Kent, England
[3] Univ York, Dept Comp Sci, York YO1 5DD, N Yorkshire, England
[4] Univ Oxford, Comp Lab, Oxford OX1 3QD, England
关键词
inductive logic programming; pharmacophore; structure-activity prediction;
D O I
10.1023/A:1007460424845
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
This paper presents a case study of a machine-aided knowledge discovery process within the general area of drug design. Within drug design, the particular problem of pharmacophore discovery is isolated, and the Inductive Logic Programming (ILP) system PROGOL is applied to the problem of identifying potential pharmacophores for ACE inhibition. The case study reported in this paper supports four general lessons for machine learning and knowledge discovery, as well as more specific lessons for pharmacophore discovery, for Inductive Logic Programming, and for ACE inhibition. The general lessons for machine learning and knowledge discovery are as follows. 1. An initial rediscovery step is a useful tool when approaching a new application domain. 2. General machine learning heuristics may fail to match the derails of an application domain, but it may be possible to successfully apply a heuristic-based algorithm in spite of the mismatch. 3. A complete search for all plausible hypotheses can provide useful information to a user, although experimentation may be required to choose between competing hypotheses. 4. A declarative knowledge representation facilitates the development and debugging of background knowledge in collaboration with a domain expert, as well as the communication of final results.
引用
收藏
页码:241 / 270
页数:30
相关论文
共 31 条
[1]   CONFORMATIONAL-ANALYSIS AND ACTIVE-SITE MODELING OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS [J].
ANDREWS, PR ;
CARSON, JM ;
CASELLI, A ;
SPARK, MJ ;
WOODS, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (03) :393-399
[2]   Three-dimensional models of ACE and NEP inhibitors and their use in the design of potent dual ACE/NEP inhibitors [J].
Bohacek, R ;
DeLombaert, S ;
McMartin, C ;
Priestle, J ;
Grutter, M .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (35) :8231-8249
[3]   ALGORITHMS FOR THE IDENTIFICATION OF 3-DIMENSIONAL MAXIMAL COMMON SUBSTRUCTURES [J].
BRINT, AT ;
WILLETT, P .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1987, 27 (04) :152-158
[4]  
BUCHANAN B, 1972, MACH INTELL, V7, P267
[5]   STRUCTURE ACTIVITY RELATIONSHIP OF MUTAGENIC AROMATIC AND HETEROAROMATIC NITRO-COMPOUNDS - CORRELATION WITH MOLECULAR-ORBITAL ENERGIES AND HYDROPHOBICITY [J].
DEBNATH, AK ;
DECOMPADRE, RLL ;
DEBNATH, G ;
SHUSTERMAN, AJ ;
HANSCH, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (02) :786-797
[6]   Solving the multiple instance problem with axis-parallel rectangles [J].
Dietterich, TG ;
Lathrop, RH ;
LozanoPerez, T .
ARTIFICIAL INTELLIGENCE, 1997, 89 (1-2) :31-71
[7]  
FAYYAD UM, 1996, ADV KNOWLEDGE DISCOV
[8]   Computer-based screening of compound databases for the identification of novel leads [J].
Finn, PW .
DRUG DISCOVERY TODAY, 1996, 1 (09) :363-370
[9]   CORRELATION OF BIOLOGICAL ACTIVITY OF PHENOXYACETIC ACIDS WITH HAMMETT SUBSTITUENT CONSTANTS AND PARTITION COEFFICIENTS [J].
HANSCH, C ;
MALONEY, PP ;
FUJITA, T .
NATURE, 1962, 194 (4824) :178-&
[10]  
HANSCH C, 1995, ACS